Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Reliability of Calcium-Binding Protein S100b Measurement Toward Optimization of Hyperosmolal Therapy in Traumatic Brain Injury Pubmed



Hendoui N1, 2 ; Beigmohammadi MT3 ; Mahmoodpoor A4 ; Ahmadi A3 ; Abdollahi M5 ; Hasanpour M6 ; Hadi F7 ; Khazaeipour Z8 ; Mousavi S9 ; Mojtahedzadeh M2
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Pharmacotherapy, Faculty of Pharmacy, Mazandaran University of Medical Science and Health Services, Sari, Iran
  2. 2. Department of Pharmacotherapy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Anesthesiology and Intensive Care Department, School of Medicine, Tehran University of Medical Science and Health Services, Tehran, Iran
  4. 4. Anesthesiology and Intensive Care Department, School of Medicine, Tabriz University of Medical Science and Health Services, Tabriz, Iran
  5. 5. Department of Toxicology and Pharmacology, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
  6. 6. Faculty of Pharmacy, Tehran University of Medical Science and Health Services, Tehran, Iran
  7. 7. Pharmaceutical Sciences Branch, Islamic Azad University, Tehran, Iran
  8. 8. Brain and Spinal Injury Repair Research Center, Research Deputy of Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran
  9. 9. Department of Pharmacotherapy, Faculty of Pharmacy, Esfehan University of Medical Science and Health Services, Esfehan, Iran

Source: European Review for Medical and Pharmacological Sciences Published:2013


Abstract

BACKGROUND: Osmotherapy is a cornerstone for the management of severe Traumatic Brain Injury (TBI). Hypertonic saline (HTS) has advantages as being preferred osmotic agent, but there is inadequte knowledge regarding dose and its saftey in comparison to mannitol. S100B, as a specific neuroinflammatory biomarker in TBI might be a reliable therapeutic index following osmotic therapy. AIM: To compare both administration ways of HTS 5% (bolus and infusion) with mannitol upon S100B as a therapeutic tool for monitoring treatment in TBI patients. METHOD: Adult patients wih modrate to severe TBI were recruited and have randomly received one of the three protocols: 125 cc of HTS 5% every 6 hrs (N: 11) as bolus; 500 cc of HTS 5% (N: 12) as infusion for 24 hrs; or 1 g/kg mannitol of 20% (N: 10) as a bolus, repeated with a dose of 0.25-0.5 g/kg every 6 hrs based on patient's response for 3 days. Serum S100B, blood pressure, serum sodium and osmolality and Glascow coma score (GCS) were measured at baseline and daily for 3 days. RESULTS: Initial serum S100B level in TBI patients was higher than control group (p < 0.0001). Levels of measured S100B have decreased for all treatment groups, but reduction wasn't significantly after hyperosmolal therapy. GCS level increased significantly in infusion group (p = 0.002) and there were negative and significant correlation between serum S100B level and GCS level in some days. Mean arterial pressure increased significantly in HTS groups (bolus: p = 0.002, infusion < 0.0001). CONCLUSIONS: S100B is closely related to the pathophysiological mechanism in TBI and may be useful as a therapeutic tool for treatment monitoring in TBI patients HTS is a safe and effective osmotic agent in TBI setting.